本研究针对移植后不良移植功能（PGF）患者造血恢复困难的临床难题，揭示了TGF-β1信号通路异常激活通过诱导骨髓内皮细胞（BM ECs）发生内皮-间质转化（EndMT），导致血管再生功能障碍和造血支持能力丧失。通过多组学分析和临床前瞻性试验，证实抑制TGF-β1 ...

本研究揭示人参皂苷Rc（gRc）通过分子对接结合TGF-β受体1（TGFBR1），抑制TGF-β信号通路并下调下游靶点核仁素（Ncl）表达，从而有效缓解氧化应激（ROS）诱导的肌肉萎缩。该发现为天然产物治疗肌肉萎缩提供了新靶点和机制依据。 研究亮点 人参皂苷Rc（gRc）通过 ...

近日，康方生物（9926.HK）宣布，其完全独立自主研发的TIGIT/TGF-β双靶点抗体融合蛋白AK130，联合PD-1/VEGF双特异性抗体新药依沃 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today will present ...

New York, USA, Sept. 23, 2025 (GLOBE NEWSWIRE) -- TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The TGF-β ...

Transforming tumor immune microenvironments with a novel systemic enveloped oncolytic virotherapy targeting all tumor sites. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

Intracellular retention of TCRαβ/CD3 to generate novel allogeneic CAR-T cells targeting CLL1 for treating acute myelocytic leukemia. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting ...